HER2-mutated NSCLC:

THE HUNT STARTS

IN FIRST LINE1

In treatment naive patients:

ORR

75 percent displayed inside a circular progress icon

(95% CI: 64, 85; N=69)
CR: 6% (n=4), PR: 70% (n=48)

DoR Range

Month calendar icon

1.5 TO 21.6+
MONTHS
(N=52)

Study Design: SOHO-01 is a global, open-label, single-arm, multicohort Phase I/II trial studying HYRNUO® in patients with HER2 (ERBB2) TKD activating mutations in locally advanced or metastatic non-squamous NSCLC.1,2

APPROVED AS A FIRST-LINE TREATMENT

for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2* TKD activating mutations.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

*HER2 is sometimes referred to as ERBB2 (erb-b2 receptor tyrosine kinase 2).

ERBB2=erythroblastic oncogene B; HER2=human epidermal growth factor 2;
TKD=tyrosine kinase domain.

Illustration of a target marker positioned within a circular cell icon

An oral TKI designed to target HER2 mutations in NSCLC

See how HYRNUO® works
Icon showing two circles labeled 10 above a no weight limit symbol

Fixed oral dosing with no weight requirement

View dosing details

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

NCCN Guidelines® recommend sevabertinib (HYRNUO®) as a 1L treatment option (NCCN Category 2A) for HER2-mutated NSCLC, and as a preferred 2L+ treatment option for certain patients who have received prior systemic therapy.3

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

ACCESS AND FINANCIAL SUPPORT IS AVAILABLE

Explore financial assistance information, patient support resources, and downloadable tools to help navigate patient access.

See financial assistance options Explore resources
Hand holding heart with cross sign icon

Bayer financial support

Insurance card icon for copay program

$0 co-pay program

Magnifying glass icon

Educational resources for you and your patients

ABBREVIATIONS

1L=first line; BICR=blinded independent central review; CI=confidence interval; CR=complete response; DoR=duration of response; FDA=Food and Drug Administration; NE=not estimable; ORR=objective response rate; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; TKI=tyrosine kinase inhibitor.

REFERENCES

  1. HYRNUO (sevabertinib). Prescribing Information. 2026.
  2. ClinicalTrials.gov. NCT05099172. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT05099172
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V9.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 12, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.